VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on February 9, 2026, regarding an event dated February 6, 2026. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "VNRX".
Key Financial Metrics and Listing Status
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses that the Company is non-compliant with NYSE American continued listing standards due to insufficient stockholders' equity relative to its loss history. Specifically, the Company has reported losses from continuing operations and/or net losses in:
- Two of its three most recent fiscal years (requiring at least $2.0 million in stockholders' equity).
- Three of its four most recent fiscal years (requiring at least $4.0 million in stockholders' equity).
- Five of its most recent fiscal years (requiring at least $6.0 million in stockholders' equity).
The Company is not eligible for exemptions based on market capitalization exceeding $50 million.
Material Changes and Regulatory Action
On February 6, 2026, the Company received a Notice from the NYSE American stating it is not in compliance with Section 1003(a) of the Company Guide. As a result:
- The Company's stock will continue to trade but will carry a ".BC" designation indicating "below compliance."
- The Company must submit a compliance plan to the NYSE American by March 8, 2026.
- The Company must regain compliance by August 6, 2027, or face delisting proceedings.
Outlook, Risks, and Management Commentary
Management intends to submit a plan to regain compliance by the March 8, 2026 deadline. The Company states the Notice has no immediate impact on ongoing business operations or SEC reporting requirements. However, the filing includes significant forward-looking risks:
- There is no assurance the Company will achieve compliance within the required timeframe.
- Failure to submit an acceptable plan or failure to make progress consistent with the plan will result in delisting.
- Delisting or continued non-compliance could materially and adversely affect the Company's stock price.
Key Facts for Investor Verification
- Verify the specific stockholders' equity balance in the most recent 10-Q or 10-K to confirm the magnitude of the deficit against the $2.0M, $4.0M, or $6.0M thresholds.
- Monitor the submission of the compliance plan by March 8, 2026, and its acceptance by the NYSE American.
- Review the ".BC" trading designation on the NYSE American for the ticker VNRX.
- Assess the Company's historical loss trends to determine which equity threshold applies.